Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
LR

NASDAQ · LRMR

Larimar Therapeutics, Inc.

Healthcare · Biotechnology

$3.93

Up+$0.02 (+0.51%)

Updated Sep 17, 2026, 5:55 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
343.65M
P/E ratio
-2.58
Dividend yield
0.00%
52-week range
$2.92 – $6.00
Volume
1.96M
Avg. volume
2.64M

Price performance

LRMR price history

1M range · 20 trading sessions · Daily adjusted prices

LRMR closed at $3.93 after 20 trading sessions, down 7.53% for the selected period.

Last close
$3.93
Period change
-7.53%
Period low
$3.78
Period high
$4.25
Daily close
View OHLC price history
LRMR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$3.93$3.97$3.825$3.931.96M
Sep 15, 2026$3.86$3.94$3.70$3.91856.62K
Sep 14, 2026$3.93$3.98$3.74$3.781.17M
Sep 11, 2026$3.91$4.07$3.85$3.922.13M
Sep 10, 2026$3.82$3.86$3.74$3.85871.39K
Sep 9, 2026$4.03$4.17$3.83$3.87978.8K
Sep 8, 2026$3.76$4.08$3.72$4.0751.04M
Sep 4, 2026$3.82$3.85$3.79$3.83391.99K
Sep 3, 2026$3.90$3.90$3.7741$3.83684.26K
Sep 2, 2026$3.96$4.075$3.8218$3.87515.56K
Sep 1, 2026$3.78$3.95$3.77$3.94755.35K
Aug 31, 2026$3.98$4.00$3.81$3.821.07M
Aug 28, 2026$4.03$4.08$3.98$4.01641.51K
Aug 27, 2026$4.16$4.16$4.02$4.05673.59K
Aug 26, 2026$4.14$4.18$4.02$4.17702.14K
Aug 25, 2026$4.08$4.235$4.08$4.161.08M
Aug 24, 2026$4.23$4.23$3.93$4.05945.55K
Aug 21, 2026$4.20$4.21$4.085$4.18699.42K
Aug 20, 2026$4.21$4.21$3.975$4.161.16M
Aug 19, 2026$4.19$4.34$4.17$4.251.23M

Latest LRMR news

The latest Smart Investors Daily articles mentioning LRMR.

Stock researchCompany · Overview

LRMR research

Overview

Company profile and research snapshot.

Company profile

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
18
LRMR recent ratings
DateFirmRatingTarget
Aug 5, 2026WedbushOutperform—
Jun 30, 2026BairdOutperform—
May 27, 2026JP MorganOverweight—
May 18, 2026WedbushOutperform—
Mar 20, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Century Therapeutics Appoints Joseph Truitt to Board of Directors

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing

Benzinga · Aug 4, 2026

Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By